Abstract
Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.
| Original language | English |
|---|---|
| Pages (from-to) | 440-442 |
| Number of pages | 3 |
| Journal | Fertility and Sterility |
| Volume | 65 |
| Issue number | 2 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- bromocriptine
- Cabergoline
- macroprolactinoma
- MRI
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. / Motta, T.; De Vincentiis, S.; Marchini, M.; Colombo, N.; D'Alberton, A.
In: Fertility and Sterility, Vol. 65, No. 2, 1996, p. 440-442.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics
AU - Motta, T.
AU - De Vincentiis, S.
AU - Marchini, M.
AU - Colombo, N.
AU - D'Alberton, A.
PY - 1996
Y1 - 1996
N2 - Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.
AB - Objective: To evaluate the effectiveness and tolerance of vaginal cabergoline in hyperprolactinemic patients intolerant to oral dopaminergics. Design: Case reports. Setting: University hospital endocrinological outpatient clinic. Patients: A 35-year-old primipara woman with idiopathic hyperprolactinemia and a 22-year-old female with primary amenorrhea harboring macroprolactinoma. Interventions: Treatment with vaginal cabergoline (0.5 mg two and five times a week). Main Outcome Measures: The serum PRL levels and side effects were assessed before and during treatment. Results: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. In the patient with idiopathic hyperprolactinemia, serum PRL levels normalized during long-term treatment, whereas in the one with macroprolactinoma they remained above the normal values (79 ng/mL [conversion factor to SI unit, 3.180]) despite resumption of menses and marked tumor shrinkage (70% reduction). No side effects were reported. Conclusions: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration.
KW - bromocriptine
KW - Cabergoline
KW - macroprolactinoma
KW - MRI
UR - http://www.scopus.com/inward/record.url?scp=0030063569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030063569&partnerID=8YFLogxK
M3 - Article
C2 - 8566276
AN - SCOPUS:0030063569
VL - 65
SP - 440
EP - 442
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 2
ER -